Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CFTR | P13569 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432453 | 0.86 | SMN1; SMN2 (0.54) | GAAALDH1A1KDM4EMEN1PSIP1 | |
| SCHEMBL31083328 | 0.85 | ALDH1A1 (0.50) | GAAALDH1A1KDM4EGLACFTR | |
| SCHEMBL964722 | 0.84 | HSD17B10 (0.49) | GAAALDH1A1KDM4EGLACFTR | |
| SCHEMBL21056695 | 0.82 | KIF11 (0.49) | GAAALDH1A1KDM4EGLACFTR | |
| SCHEMBL29441687 | 0.81 | SLC6A3 (0.61) | GAAALDH1A1CFTRMEN1MAPT | |
| SCHEMBL3920552 | 0.81 | SLC6A3 (0.61) | GAAALDH1A1CFTRMEN1MAPT | |
| SCHEMBL2898125 | 0.80 | SLC6A4 (0.51) | GAAALDH1A1KDM4EGLAMEN1 | |
| SCHEMBL31325674 | 0.79 | KDM4E (0.57) | GAAALDH1A1KDM4EGLACFTR | |
| SCHEMBL21056912 | 0.76 | ALDH1A1 (0.53) | GAAALDH1A1KDM4EGLACFTR | |
| SCHEMBL28409137 | 0.76 | GAA (0.50) | GAAALDH1A1KDM4ECFTRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366016-B1 | PROCESS FOR THE PREPARATION OF ARYLETHANOLDIAMINES USEFUL AS AGONISTS OF THE BETA-3-ADRENOCEPTOR | GLAXO GROUP LTD (GB) | 2010-08-25 | — | — | EP | disclosed |
| EP-1366016-B1 | PROCESS FOR THE PREPARATION OF ARYLETHANOLDIAMINES USEFUL AS AGONISTS OF THE BETA-3-ADRENOCEPTOR | GLAXO GROUP LTD (GB) | 2010-08-25 | — | — | EP | disclosed |
| US-7709677-B2 | e.g.3-{3-[(2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]phenyl}isonicotinic acid ; useful as agonists at atypical beta-adrenoceptors; treatment of hyperglycaemia, animal growth promoters, blood platelet aggregation inhibitors, as positive inotropic agents and antiatherosclerotic agent | GLAXOSMITHKLINE LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709677-B2 | e.g.3-{3-[(2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]phenyl}isonicotinic acid ; useful as agonists at atypical beta-adrenoceptors; treatment of hyperglycaemia, animal growth promoters, blood platelet aggregation inhibitors, as positive inotropic agents and antiatherosclerotic agent | GLAXOSMITHKLINE LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709677-B2 | e.g.3-{3-[(2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]phenyl}isonicotinic acid ; useful as agonists at atypical beta-adrenoceptors; treatment of hyperglycaemia, animal growth promoters, blood platelet aggregation inhibitors, as positive inotropic agents and antiatherosclerotic agent | GLAXOSMITHKLINE LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080306278-A1 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306278-A1 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306278-A1 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-7425639-B2 | For preparing arylethanoldiamines which are agonists of beta-adrenoceptors; fewer steps, the regioselectivity of epoxide opening is highly selective; novel chemical intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425639-B2 | For preparing arylethanoldiamines which are agonists of beta-adrenoceptors; fewer steps, the regioselectivity of epoxide opening is highly selective; novel chemical intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-20040077868-A1 | For preparing arylethanoldiamines which are agonists of beta-adrenoceptors; fewer steps, the regioselectivity of epoxide opening is highly selective; novel chemical intermediates | B3AR THERAPEUTICS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1366016-A2 | PROCESS FOR THE PREPARATION OF ARYLETHANOLDIAMINES USEFUL AS AGONISTS OF THE BETA-3-ADRENOCEPTOR | GLAXO GROUP LIMITED (GB) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002066418-A2 | PROCESS FOR THE PREPARATION OF ARYLETHANOLDIAMINES USEFUL AS AGONISTS OF THE BETA-3-ADRENOCEPTOR | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
| WO-2001042217-A1 | BETA-3 ADRENOCEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077868-A1 | For preparing arylethanoldiamines which are agonists of beta-adrenoceptors; fewer steps, the regioselectivity of epoxide opening is highly selective; novel chemical intermediates | ADRB3, ADRB2, ADRB1 | GAA 3024/4885ALDH1A1 248/4885KDM4E 1116/4885 |
| US-20080306278-A1 | PROCESS | ADRB3, ADRA1D, ADRB1 | GAA 1528/4885ALDH1A1 459/4885KDM4E 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.